血浆蛋白可预测2型糖尿病患者的肾功能轨迹
研究纳入SMART2D队列1285例及糖尿病肾病队列798例2型糖尿病且基线eGFR≥60 mL/min/1.73 m2的患者,用潜类别混合模型识别出缓慢下降(92.2%)、渐进性下降(4.0%)和加速下降(3.8%)三种eGFR轨迹。在SMART2D队列分析的1448种蛋白中,19种蛋白与加速下降相关、1种蛋白与渐进性下降相关,独立于传统心肾危险因素;加入这些蛋白后,加速下降预测的AUC提高至0.93(delta 0.09,P < .001)。
要点
- 识别出缓慢下降(92.2%)、渐进性下降(4.0%)和加速下降(3.8%)三种eGFR轨迹。
- 加速下降组进展至终末期肾病的风险最高(log-rank检验P < .0001)。
- 19种蛋白与加速下降相关、1种蛋白与渐进性下降相关,独立于传统心肾危险因素。
核心结论
- 不同的血浆蛋白与渐进性和加速性eGFR下降相关,独立于传统心肾危险因素,其中一些蛋白可增强2型糖尿病患者eGFR轨迹的预测。
研究设计与样本
- 在SMART2D队列(n = 1285)和糖尿病肾病队列(n = 798)的2型糖尿病且基线eGFR ≥60 mL/min/1.73 m2患者中,采用潜类别混合模型分析识别eGFR轨迹模式。
- 在SMART2D队列中采用多变量logistic回归评估蛋白组与eGFR轨迹的关联。
主要发现
- 在SMART2D队列中识别出缓慢下降(92.2%)、渐进性下降(4.0%)和加速下降(3.8%)三种eGFR轨迹组,并在糖尿病肾病队列中得到验证。
- 加速下降组参与者进展至终末期肾病的风险最高(log-rank检验,P < .0001)。
- 在SMART2D队列分析的1448种蛋白中,19种蛋白与加速下降相关,包括KIM-1(OR = 2.95;95% CI,2.01-4.32;P = 2.95 × 10-8)、MMP7(OR = 16.5;95% CI,5.54-49.07;P = 4.61 × 10-7)和VSIG4(OR = 7.38;95% CI,3.22-16.89;P = 2.24 × 10-6)。
- 1种蛋白与渐进性下降相关(OR = 6.34;95% CI,2.77-14.52;P = 1.26 × 10-5),独立于包括基线肾功能在内的传统心肾危险因素。
- 将这些蛋白加入临床危险因素(年龄、性别、 ethnicity、eGFR、尿白蛋白与肌酐比值、HbA1c、糖尿病病程、收缩压、甘油三酯)后,渐进性下降的曲线下面积提高至0.77(delta 0.04,P = .057),加速下降提高至0.93(delta 0.09,P < .001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The rate of decline in estimated glomerular filtration rate (eGFR) varies among patients with type 2 diabetes (T2D). We aimed to identify plasma proteins associated with diverse eGFR trajectories in T2D. METHODS: We performed latent class mixed models analysis among patients with T2D and relatively preserved kidney function (baseline eGFR ≥60 mL/min/1.73 m2) from the Singapore Study of Macro-angiopathy and Micro-Vascular Reactivity in Type 2 Diabetes (SMART2D) (n = 1285) and diabetic nephropathy (n = 798) cohorts to identify patterns of eGFR trajectories. Comprehensive proteomic association with eGFR trajectories was assessed using multivariable logistic regression in the SMART2D cohort. RESULTS: Three distinct eGFR trajectories groups-slow decline (92.2%), progressive decline (4.0%), and accelerated decline (3.8%)-were identified in SMART2D and validated in the diabetic nephropathy cohort. Participants in the accelerated decline group exhibited the highest risk of progression to end-stage kidney disease (log-rank test, P < .0001). Among 1448 proteins analyzed in the SMART2D cohort, 19 proteins, including KIM-1 (odds ratio [OR] = 2.95; 95% CI, 2.01-4.32; P = 2.95 × 10-8), MMP7 (OR = 16.5; 95% CI, 5.54-49.07; P = 4.61 × 10-7), and VSIG4 (OR = 7.38; 95% CI, 3.22-16.89; P = 2.24 × 10-6), were associated with accelerated decline and 1 protein (OR = 6.34; 95% CI, 2.77-14.52; P = 1.26 × 10-5) was associated with progressive decline, independent of traditional cardiorenal risk factors including baseline kidney function. Adding these proteins to clinical risk factors (age, sex, ethnicity, eGFR, urine albumin-to-creatinine ratio, HbA1c, diabetes duration, systolic blood pressure, triglyceride) improved area under the curve to 0.77 (delta 0.04, P = .057) for progressive decline and 0.93 (delta 0.09, P < .001) for accelerated decline. CONCLUSION: Different plasma proteins are associated with progressive and accelerated eGFR decline, independent of traditional cardiorenal risk factors, some of which enhance eGFR trajectory prediction in patients with T2D.
引用
- Gurung RL, Zheng H, Tan JLI, et al. Plasma Proteins Predict Kidney Function Trajectories in Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39950984. doi:10.1210/clinem/dgaf095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。